Pierre Fabre’s Braftovi becomes first targeted therapy approved for BRAF-mutant colorectal cancer in Europe

France-based Laboratoires Pierre Fabre has received European Commission approval for Braftovi (encorafenib) in combination with cetuximab and FOLFOX (fluorouracil, leucovorin, and oxaliplatin) as first-line treatment for adult patients with BRAF V600E-mutant metastatic colorectal cancer. The decision establishes the first EU-approved targeted therapy in this setting, addressing a patient population for whom outcomes under standard chemotherapy have historically been poor.

The approval covers the triplet regimen of encorafenib, cetuximab, and modified FOLFOX6 (mFOLFOX6). Encorafenib is an oral, selective BRAF kinase inhibitor; combined with cetuximab, an anti-EGFR monoclonal antibody, the pairing is designed to suppress both primary BRAF V600E-driven signaling and compensatory EGFR-mediated feedback reactivation of the MAPK pathway — a resistance mechanism that limits the efficacy of single-agent BRAF inhibition in colorectal tumors. The addition of mFOLFOX6 chemotherapy to this targeted backbone reflects the more aggressive disease biology characteristic of BRAF V600E-mutant mCRC relative to other molecular subtypes. As noted in coverage of next-generation BRAF inhibitors, paradoxical MAPK reactivation remains a class-wide challenge that combination strategies are specifically designed to mitigate.

The EC decision was supported by data from the Phase III BREAKWATER trial, which enrolled previously untreated patients with BRAF V600E-mutant mCRC. The study used dual primary endpoints of objective response rate and progression-free survival. Encorafenib plus cetuximab and mFOLFOX6 demonstrated a statistically significant improvement in PFS compared with oxaliplatin-based chemotherapy with or without bevacizumab, with a median PFS of 12.8 versus 7.1 months (hazard ratio 0.53; 95% CI, 0.41–0.68). The regimen also demonstrated a statistically significant overall survival benefit, reducing the risk of death by 51% versus the control arm.

BRAF V600E mutations occur in approximately 8–10% of mCRC cases and are associated with a distinctly aggressive clinical course and poor response to conventional chemotherapy. Prior to this approval, no targeted therapy had been authorized in the EU for the first-line treatment of this molecularly defined population. The prior EU-approved use of encorafenib plus cetuximab — without the FOLFOX backbone — was restricted to previously treated patients, leaving the first-line setting without a biomarker-directed option. The first-line mCRC landscape has lacked approved targeted options for non-KRAS G12C-mutant populations, a gap this approval now partially addresses for the BRAF V600E subgroup.

The AllSci BriefSystematic R&D and deal news. Daily.

The active comparator in BREAKWATER — bevacizumab (Avastin, Roche/Genentech) combined with mFOLFOX6, FOLFOXIRI, or CAPOX — represented the pre-existing standard of care for this population. The magnitude of PFS improvement and the OS signal reported in BREAKWATER position the encorafenib-based triplet as a clinically meaningful advance over that benchmark.

Pierre Fabre holds exclusive commercialization rights for encorafenib in Europe under a licensing arrangement originally established with Array BioPharma in 2015, rights that remained with Pierre Fabre following Pfizer’s 2019 acquisition of Array. The EC approval represents a meaningful expansion of the encorafenib franchise for the company in its core European market.


This article was generated with AI assistance and reviewed and edited by the AllSci editorial team Explore more at AllSci News: https://allsci.com/news/